Comparative clinical study of the efficacy and safety of a S-metoprolol ER tablet versus a racemate metoprolol ER tablet in patients with chronic stable angina

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 5, 2007, Pages 253-258

  Aneja, Panka ^a   Srinivas, A ^b   Das Biswas, A ^c  

^a Department of Care and Cure ^*  (India)

^b Vikram Hospital   (India)

^c R G KAR MEDICAL COLLEGE   (India)

Author keywords

Angina; Efficacy; S metoprolol; Safety

Indexed keywords

ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; METOPROLOL; METPURE XL; SELOKEN XL; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ECG ABNORMALITY; FATIGUE; FEMALE; HEART RATE; HUMAN; HYPERTENSION; INDIAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PROSPECTIVE STUDY; RACEMIC MIXTURE; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE; TABLET; XEROSTOMIA;

EID: 34248351229     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45253     Document Type: Article

References (10)

1. 2 adrenergic receptors in human atherosclerotic coronary arteries. Circulation. 2005; 111: 288-294.
2. Bortone AS, Hess OM, Gaglione A, Suter T, Nonogi H, Grimm J, Krayenbuehl HP. Effect of intravenous propranolol on coronary vasomotion at rest and during dynamic exercise in patients with coronary artery disease. Circulation. 1990; 81: 1225-1235.
3. Dwivedi SK, Saran RK, Mittal S, Gupta R, Narain VS, Puri VK. Silent ischemic interval on exercise test is a predictor of response to drug therapy: a randomized. crossover trial of metoprolol versus diltiazem in stable angina. Clin Cardiol. 2001; 24: 45-49.
4. Mehvar R, Brocks D. Stereospecific pharmacokinetics and pharmacodynamics of β-adrenergic blockers in humans. J Pharm Pharmaceut Sci. 2001; 4: 185-200.
5. Nathanson JA. Stereospecificity of β-adrenergic antagonists: R-enantiomers show increased selectivity for β-2 receptors in ciliary process. J Pharmacol Exp Ther. 1988; 245: 94-101.
6. Jayaram S, Kaul U, Pai V, Pandit A, Pathak L, Shinde SN, Thakur AK The SMART Trial (S-Metoprolol Assessment in Hypertension Trial. Cardiology Today. 2005; IX: 222-229.
7. Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with β-blockers: importance of ancillary properties. Prog Cardiovasc Dis. 1997; 39: 445-456.
8. Stoschitzky K, Lindner W, Zernig G. Racemic beta-blockers - fixed combinations of different drugs. J Clin Bas Cardiol. 1998; 1: 15-19.
9. Wahlund G, Nerme N, Abrahamsson T, Sjoquist PO. The β1 - and β-adrenoceptor affinity and β1-blocking potency of S- and R-metoprolol. Br J Pharmacol. 1990; 99: 592-596.
10. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with Metoprolol in patients with hypertension: mortality results from the MAPHY study. JAMA 1988; 259: 1976-1982.